Dr Othman Ahmad Othman

About

I graduated with First-Class Honour BSc Degree in Pharmacy from the School of Pharmacy, University of Mosul, Mosul, Iraq in 2006, following which I commenced a MSc Degree in the Department of Pharmacology, School of Medicine, University of Mosul, Mosul, Iraq, assessing the effect of continuous valproate monotherapy on body mass index (BMI), serum leptin, malondialdehyde (MDA) and lipid profile in male epileptic children and adult patients in comparison to healthy male controls, and I graduated in 2010 with First-Class Honour MSc Degree in Pharmacology. Thereafter, I conduced a PhD Degree at the School of Life Sciences, University of Nottingham, Nottingham, England, UK. I characterized the effects of reducing the levels of the NAD precursor nicotinamide mononucleotide (NMN) with the NMN-synthesizing enzyme nicotinamide phosphoribosyl transferase (NAMPT) inhibitor FK866 on axonal damage and behavioural symptoms in in vitro and in vivo models of neurodegeneration including Huntington’s disease (HD) and Alzheimer’s disease (AD), and I graduated in 2016. Next, I worked as Post-Doctoral Research Fellow at The University of Nottingham, and I lead many Translational Pharmacology projects with broad range of national and international collaborators, both from the public and private sectors, including other UK universities, pharmaceutical companies, NHS, and others. In addition, I actively participated in designing, teaching, learning, delivering, and assessing pharmacology and broad range of medical and biomedical science subjects to undergraduate and postgraduate students at The University of Nottingham and Nottingham Trent University. Current Responsibilities: I am currently The Medicine BMedSci Year 1 Lead, and The Medicine BMedSci Pharmacology Lead, and responsible for the operational management of the curriculum, mainly across Year 1 of the Early Years and the BMedSci component of the University of Nottingham’s Medicine programme. In addition, I convene number of teaching modules at The School of Pharmacy, and School of Medicine, University of Nottingham, and lead The Pharmacology and Therapeutics Theme for many teaching modules at The School of Pharmacy, University of Nottingham. Moreover, I deliver teaching (in variety of settings including large group lectures and small group tutorials as well as, workshops, and practical classes) across range of courses, including: • Pharmacy MPharm Course (UCAS: B230) at The School of Pharmacy, University of Nottingham (ranked top 5 course in the world for pharmacy and pharmacology in QS World University Rankings by Subject 2022 and 2021). • Pharmacology BSc Course (UCAS: B211) at The School of Life Sciences, University of Nottingham (ranked top 5 course in the world for pharmacy and pharmacology in QS World University Rankings by Subject 2022 and 2021). • Medicine BMedSci and BMBS Courses (Bachelor of Medical Sciences, and Bachelor of Medicine and Surgery) (UCAS: A100) at The School of Medicine, University of Nottingham. • Drug Discovery MSc Course through collaboration from both The School of Pharmacy and School of Life Sciences, University of Nottingham. Besides that, I have other responsibilities, including: • Working as Senior Tutor for Drug Discovery MSc Course and Personal Tutor for Pharmacy MPharm Course at The School of Pharmacy, University of Nottingham. • Supervising undergraduate Pharmacy, and Pharmacology project students, and postgraduate MSc and PhD students at The University of Nottingham. • Contributing to EC Panel Meetings and Internal and External Exam Board Meetings at The School of Pharmacy, and School of Medicine, University of Nottingham. • Designing, reviewing, assessing, and moderating various written, online, OSCE and IP oral exams at The School of Pharmacy, and School of Medicine, University of Nottingham. Current Research Neuroinflammation plays a pivotal role in the aetiology of neurodegenerative diseases like Alzheimer's and Parkinson's diseases. Chronic neuroinflammation is associated with a cascade of self-propagating cellular events including blockade of glutamate uptake by glia, and enhanced release of glutamate. Drugs that attenuate the pre-synaptic release of glutamate at neuronal G protein-coupled receptors, including A1 and A2A adenosine receptors, have been shown to reduce the neuroinflammatory response of microglia cells. Our research focus on assessing the anti-inflammatory effects of these drugs in in vitro and in vivo models of neurodegeneration.

Education

Publications